SEMA4D/CD100: As an Important Immunoregulator to Improve ImmunotherapyIn April 2022, the American Association for Cancer Research (AACR) annual meeting announced phase 1b/2 clinical data (NCT04815720) for Pepinemab, the first SEMA4D-targeted antibody for the treatment of recurrent or metas...
Detailed information

GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology...
Detailed information

ROR1, an Emerging Target for Tumor ImmunotherapyROR1 has emerged as a key target, with multiple pharmaceutical companies advancing ROR1-targeted drugs into clinical trials. Recently, Merck & Co. acquired Zilovertamab Vedotin (MK-2140) for $2.75 billion, and its clinic...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaPfizer announced that its TFPI antibody, Marstacimab (brand name Hympavzi), has been approved by the FDA. This marks a significant advance in hemophilia treatment. Hympavzi is the first FDA-approved TFPI antibody and pro...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

Streamlining Antibody Internalization Assessment with DT3C: Accelerating ADC Candidate SelectionThe development of antibody-drug conjugates (ADCs) has revolutionized cancer therapy by enabling targeted delivery of cytotoxic agents to cancer cells. ADC's anti-cancer efficacy depends on its internalization efficiency...
Detailed information

ANGPT2 (Ang-2): the First Bispecific Antibody for Eye Vision Loss Therapy, a Novel Target for Tumor Angiogenesis!On January 28, 2022, the FDA approved the first bispecific antibody Vabysmo (Ang-2 x VEGF-A) for eye, to treat two leading causes of vision loss--wet age-related macular degeneration (AMD) and diabetic macular edema (DME...
Detailed information

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM)GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) has emerged as a promising therapeutic target, garnering significant attention in the field of oncology and immunotherapy. Particularly in the treatment of mul...
Detailed information

CXCR4: An Attractive Target of GPCR family Brings Promising New Drugs for Cancer Therapy！BioLineRx Ltd presently has completed a successful pre-New Drug Application (NDA) meeting regarding a chemokine receptor CXCR4 antagonist (Motixafortide), from a report on January 18, 2022. In particular, the biopharmace...
Detailed information

The Collection of Progress of Anti-GPCR Antibody DrugsAs mentioned in the article entitled "G protein-Coupled Receptor - Targets for Drug Therapy", GPCRs is an important drug target, and currently about 40% of the marketed drugs are designed based on GPCRs. About 34% of dru...
Detailed information